Director, Epidemiology Forecasting

Job Description

Vertex operates at the forefront of scientific innovation and has successfully developed and commercialized multiple breakthrough medicines for cystic fibrosis (CF), as well as Casgevy, a gene therapy for sickle cell disease and beta-thalassemia. Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases including programs in pain, APOL-1 mediated kidney disease (AMKD), and cell therapies for type 1 diabetes, among others.

Vertex recently acquired Alpine Immune Sciences. Alpine’s lead molecule, povetacicept (ALPN-303), is a highly potent and effective dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand). Povetacicept holds the potential to benefit patients with a range of diseases, including autoimmune diseases of the kidney and autoimmune cytopenias.

In consideration of the expanding pipeline, Vertex is expanding its E...